Results 51 to 60 of about 19,637 (185)

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (2014)

, 2014
Background: Ezetimibe reduces absorption of dietary and biliary cholesterol by inhibiting its transport across the intestinal wall. Ezetimibe receives public subsidy in Australia from the Pharmaceutical Benefits Scheme (PBS) for very restricted ...
Susan, Tett, Martin, Jennifer, Michael, David, Ostini, Remo, Hollingworth, Samantha A.   +4 more
core   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

Synthesis and Modeling of Ezetimibe Analogues

, 2021
Ezetimibe is a well-known drug that lowers blood cholesterol levels by reducing its absorption in the small intestine when joining to Niemann-Pick C1-like protein (NPC1L1).
David Díez, Alejandro Manchado, Mateo M. Salgado, Carlos T. Nieto, Narciso M. Garrido   +4 more
core   +1 more source

Stability Indicating Liquid Chromatographic Method for the Simultaneous Determination of Rosuvastatin and Ezetimibe from Pharmaceuticals and Biological Samples

Journal of the Turkish Chemical Society, Section A: Chemistry, 2020
Fixed dose combinations of ezetimibe and rosuvastatin are well known to provide significantly superior efficacy to rosuvastatin alone in lowering total cholesterol, and triglyceride levels.
Sevinç KURBANOĞLU, Ozgur ESİM, Cansel KOSE OZKAN, Ayhan SAVAŞER , Yalcin OZKAN, Bengi USLU , Sibel ÖZKAN   +6 more
doaj  

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source

Pharmacological Targets for Periodontitis: A Systematic Review of Drug‐Target Mendelian Randomisation Studies

Journal of Periodontal Research, EarlyView.
This systematic review evaluated drug‐target Mendelian randomisation studies on periodontitis. Twelve studies identified host‐response‐related targets mainly involved in inflammatory, complement, and immune pathways. Although some targets were linked to existing drugs, the evidence remains preliminary and heterogeneous, requiring replication and ...
Luigi Nibali, Jing Kang, Simon Haworth, Alessandro Polizzi, Gaetano Isola   +4 more
wiley   +1 more source

Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets [PDF]

, 2008
BACKGROUND: Though guidelines emphasize low-density lipoprotein cholesterol (LDL-C) lowering as an essential strategy for cardiovascular risk reduction, achieving target levels may be difficult.
Westphal, Ronja, Geist, Volker, Richardt, Gert, Herrmann, Lutz, Tölg, Ralph, Abdel-Wahab, Mohamed, Liska, Branislav, Khattab, Ahmed A   +7 more
core   +2 more sources

Validation of the European Society of Cardiology Ischemic and Bleeding Risk Criteria for Risk Stratification After Endovascular Therapy in Japanese Patients With Lower Extremity Artery Disease

Catheterization and Cardiovascular Interventions, Volume 108, Issue 3, Page 801-815, September 1, 2026.
ABSTRACT Background The European Society of Cardiology (ESC) guidelines for peripheral artery disease recommend antithrombotic strategies based on high ischemic risk (HIR) and high bleeding risk (HBR) criteria. However, their prognostic value in patients with lower extremity artery disease (LEAD) undergoing endovascular therapy (EVT) remains unclear ...
Hirokazu Shimono, Daisuke Kanda, Akihiro Tokushige, Nobuhiro Ito, Yutaro Nomoto, Hiroyuki Tabata, Kenta Ohmure, Takuro Kubozono, Mitsuru Ohishi   +8 more
wiley   +1 more source